Despite sales of its approved antibody-drug conjugate (ADC) Adcetris at levels described by analysts as "flat," Seattle Genetics Inc. scored an expansion of the deal begun last year with Abbott. The arrangement brings $25 million up front in exchange for Abbott's right to use the auristatin-based ADC technology against more targets than before.